These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 2940960

  • 1. Dopamine D2 receptor density remains constant in treated Parkinson's disease.
    Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW.
    Ann Neurol; 1986 May; 19(5):487-92. PubMed ID: 2940960
    [Abstract] [Full Text] [Related]

  • 2. Dopamine D2 receptor density in parkinsonian brain is constant for duration of disease, age, and duration of L-dopa therapy.
    Guttman M, Seeman P.
    Adv Neurol; 1987 May; 45():51-7. PubMed ID: 2950731
    [No Abstract] [Full Text] [Related]

  • 3. Reduced D2 dopamine and muscarinic cholinergic receptor densities in caudate specimens from fluctuating parkinsonian patients.
    Ahlskog JE, Richelson E, Nelson A, Kelly PJ, Okazaki H, Tyce GM, van Heerden JA, Stoddard SL, Carmichael SW.
    Ann Neurol; 1991 Aug; 30(2):185-91. PubMed ID: 1654766
    [Abstract] [Full Text] [Related]

  • 4. L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.
    Guttman M, Seeman P.
    J Neural Transm; 1985 Aug; 64(2):93-103. PubMed ID: 2934514
    [Abstract] [Full Text] [Related]

  • 5. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ, Jenner P.
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [Abstract] [Full Text] [Related]

  • 6. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK, Rinne JK, Rinne JO, Laakso K, Tenovuo O, Lönnberg P, Koskinen V.
    J Neural Transm Suppl; 1983 Sep; 19():163-71. PubMed ID: 6321647
    [Abstract] [Full Text] [Related]

  • 7. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
    Calon F, Dridi M, Hornykiewicz O, Bédard PJ, Rajput AH, Di Paolo T.
    Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
    [Abstract] [Full Text] [Related]

  • 8. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease.
    Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y.
    Brain; 2008 Jan; 131(Pt 1):120-31. PubMed ID: 17956909
    [Abstract] [Full Text] [Related]

  • 9. Alteration of dopamine receptors in the caudate nucleus and the putamen in schizophrenic brain.
    Mjörndal T, Winblad B.
    Med Biol; 1986 Jan; 64(6):351-4. PubMed ID: 2881030
    [Abstract] [Full Text] [Related]

  • 10. Dopamine D-1 receptors in the parkinsonian brain.
    Rinne JO, Rinne JK, Laakso K, Lönnberg P, Rinne UK.
    Brain Res; 1985 Dec 16; 359(1-2):306-10. PubMed ID: 2934111
    [Abstract] [Full Text] [Related]

  • 11. [The L-dopa test in Parkinson's disease].
    Esteguy M, Bonnet AM, Kefalos J, Lhermitte F, Agid Y.
    Rev Neurol (Paris); 1985 Dec 16; 141(5):413-5. PubMed ID: 4048732
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB, Bernardi G.
    Trends Pharmacol Sci; 2005 Jul 16; 26(7):341-4. PubMed ID: 15936832
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors.
    Churchyard A, Donnan GA, Hughes A, Howells DW, Woodhouse D, Wong JY, Kalnins RM, Mendelsohn FA, Paxinos G.
    Ann Neurol; 1993 Aug 16; 34(2):219-26. PubMed ID: 8338346
    [Abstract] [Full Text] [Related]

  • 19. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov 16; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 20. Effect of the putative dopamine D1 agonist and D2 antagonist FCE 23884 on Parkinson's disease.
    Metman LV, Blanchet PJ, de Jong D, Mouradian MM, Chase TN.
    Mov Disord; 1996 May 16; 11(3):257-60. PubMed ID: 8723141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.